Cargando…

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia

Tisagenlecleucel is a first-in-class chimeric antigen receptor (CAR) T-cell therapy approved by the US Food and Drug Administration in 2017 for relapsed/refractory (RR) acute lymphoblastic leukemia (ALL) in patients up to 25 years of age. Tisagenlecleucel is an autologous T-cell therapy that is gene...

Descripción completa

Detalles Bibliográficos
Autor principal:	Freyer, Craig W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505546/ https://www.ncbi.nlm.nih.gov/pubmed/31086690

Ejemplares similares

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation
por: Ipe, Abraham, et al.
Publicado: (2023)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023)

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023)

Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: v. Stackelberg, Arend, et al.
Publicado: (2023)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2018)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Spontaneous remission of acute lymphoblastic leukemia: A case report
por: Höres, Timm, et al.
Publicado: (2018)

Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2019)

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia
por: Guarini, Anna, et al.
Publicado: (2023)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective
por: Yang, Hongbo, et al.
Publicado: (2020)

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
por: Sheykhhasan, Mohsen, et al.
Publicado: (2022)

Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
por: Shah, Gaurav, et al.
Publicado: (2019)

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
por: Sugita, Mayumi, et al.
Publicado: (2023)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
por: Elreda, Lauren, et al.
Publicado: (2014)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

First-line treatment of acute lymphoblastic leukemia with pegasparaginase
por: Masetti, Riccardo, et al.
Publicado: (2009)

Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement
por: Gye, Amy, et al.
Publicado: (2022)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

New cars on the highways: Trends in injuries and outcomes following ejection
por: Manguso, Nicholas, et al.
Publicado: (2019)

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
por: Hashem Boroojerdi, Mohadese, et al.
Publicado: (2020)

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
por: Davila, Marco L., et al.
Publicado: (2013)

DNA Methylation Analysis of Bone Marrow Cells at Diagnosis of Acute Lymphoblastic Leukemia and at Remission
por: Nordlund, Jessica, et al.
Publicado: (2012)

Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment
por: Gkazi, Soragia Athina, et al.
Publicado: (2022)

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
por: Wang, Xiao Jun, et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6372279tmjo4qghffe73gb1k6m